3SBio stock trades at HKD 15.76 as new products lift growth case
Published on 09/29/2026 at 06:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
3SBio stock was trading at HKD 15.76 on the Hong Kong Stock Exchange on September 29, 2026, up 0.90 percent from the prior close, while its market capitalization stood at HKD 39.4 billion. The key question is whether new products and the CDMO business can offset pressure on established biologics.
Revenue growth meets profit pressure
According to Futunn on September 22, 2026, 3SBio reported first-half 2026 revenue of RMB 4.526 billion, up 3.9 percent year over year. Net profit attributable to equity holders fell 15.6 percent to RMB 1.147 billion, while adjusted operating profit attributable to equity holders increased 26.5 percent to RMB 1.436 billion.
The mix explains the uneven result. Biologics sales totaled RMB 3.443 billion in the first half of 2026, down 19.31 percent, while CDMO revenue reached RMB 231 million, up 160.87 percent. That contrast gives investors a measurable transition story rather than a simple growth narrative.
Analyst target stays above HKD 30
As The Globe and Mail reported on September 20, 2026, Shenwan Hongyuan maintained a Buy rating and set a HKD 30.40 price target. The same report cited a consensus target of HKD 29.34, placing both reference points materially above the September 29 trading price.
The valuation case depends on execution in the pipeline. The first-half analysis linked the CDMO increase to clinical development of PF-08634404/707 and identified newly approved innovative products as potential growth drivers, while healthcare reimbursement controls and centralized procurement remain direct risks to existing product revenue.
Buybacks add a capital signal
According to Futunn on September 16, 2026, 3SBio repurchased 1.7 million shares for HKD 26.775 million at HKD 15.70 to HKD 15.79 per share. The buyback prices sit close to the September 29 quote, adding a concrete capital-allocation reference as the company shifts toward innovative medicines and CDMO growth.
Stock remains below yearly high
3SBio stock was last at HKD 15.76 on September 29, 2026 at 11:59 a.m. HKT, with volume of 16,099,553 shares. The 52-week range was HKD 14.81 to HKD 35.42, leaving the quote HKD 19.66 below the high and HKD 0.95 above the low.
3SBio stock snapshot
- Company: 3SBio Inc.
- Ticker: 01530
- Trading venue: Hong Kong Stock Exchange
- Price (as of September 29, 2026, 11:59 a.m. HKT): HKD 15.76
- Market capitalization: HKD 39.4 billion (as of September 29, 2026)
- 52-week range: HKD 14.81-35.42 (as of September 29, 2026)
- Sector / Industry: Health Care / Biotechnology
- Volume: 16,099,553 shares (September 29, 2026)
